Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML (2019)

First Author: Basheer F
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.37804

Publication URI: https://www.repository.cam.ac.uk/handle/1810/290577

Type: Journal Article/Review